SI2201376T1 - Nov biomarker za monitoring razvoja bolezni in določanje učinkovitosti terapij - Google Patents

Nov biomarker za monitoring razvoja bolezni in določanje učinkovitosti terapij

Info

Publication number
SI2201376T1
SI2201376T1 SI200830723T SI200830723T SI2201376T1 SI 2201376 T1 SI2201376 T1 SI 2201376T1 SI 200830723 T SI200830723 T SI 200830723T SI 200830723 T SI200830723 T SI 200830723T SI 2201376 T1 SI2201376 T1 SI 2201376T1
Authority
SI
Slovenia
Prior art keywords
therapies
assessing
efficacy
diseases
new biomarker
Prior art date
Application number
SI200830723T
Other languages
English (en)
Slovenian (sl)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of SI2201376T1 publication Critical patent/SI2201376T1/sl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • G01N2800/245Transplantation related diseases, e.g. graft versus host disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/324Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
SI200830723T 2007-10-24 2008-10-15 Nov biomarker za monitoring razvoja bolezni in določanje učinkovitosti terapij SI2201376T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
EP08842581A EP2201376B1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies
PCT/FI2008/050576 WO2009053523A1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies

Publications (1)

Publication Number Publication Date
SI2201376T1 true SI2201376T1 (sl) 2012-09-28

Family

ID=38656804

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200831377T SI2503338T1 (sl) 2007-10-24 2008-10-15 CD73 kot biomarker za spremljanje razvoja bolezni in ocenjevanje učinkovitosti terapij
SI200830723T SI2201376T1 (sl) 2007-10-24 2008-10-15 Nov biomarker za monitoring razvoja bolezni in določanje učinkovitosti terapij

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200831377T SI2503338T1 (sl) 2007-10-24 2008-10-15 CD73 kot biomarker za spremljanje razvoja bolezni in ocenjevanje učinkovitosti terapij

Country Status (14)

Country Link
US (1) US20100209942A1 (enExample)
EP (2) EP2201376B1 (enExample)
JP (2) JP4982610B2 (enExample)
KR (2) KR20100059902A (enExample)
CA (1) CA2702635A1 (enExample)
CY (2) CY1113403T1 (enExample)
DK (2) DK2201376T3 (enExample)
ES (2) ES2389751T3 (enExample)
FI (1) FI20070795A0 (enExample)
HR (2) HRP20120743T1 (enExample)
PL (2) PL2201376T3 (enExample)
PT (2) PT2201376E (enExample)
SI (2) SI2503338T1 (enExample)
WO (1) WO2009053523A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2712303C (en) 2008-01-18 2015-03-31 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
BR112013001754A2 (pt) 2010-07-23 2016-05-31 Harvard College método para detectar marcas de doença ou condições em fluídos corpóreos
EP2596134B1 (en) 2010-07-23 2020-04-08 President and Fellows of Harvard College Methods of detecting diseases or conditions using phagocytic cells
WO2012012694A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
US20130210647A1 (en) 2010-07-23 2013-08-15 President And Fellows Of Harvard College Methods of Detecting Cardiovascular Diseases or Conditions
BR112014031365A2 (pt) 2012-06-15 2017-06-27 Stylli Harry métodos de detectar doenças ou condições
SG11201408383SA (en) 2012-06-15 2015-01-29 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
BR112015018213B1 (pt) 2013-02-14 2022-12-20 Faron Pharmaceuticals Oy Métodos para determinar a síndrome da angústia respiratória aguda (ards) e para monitorar o desenvolvimento desta e kit para diagnóstico
EP4513187A3 (en) 2013-03-09 2025-05-21 Immunis.AI, Inc. Methods of detecting prostate cancer
WO2014164366A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting cancer
EP4075139B1 (en) 2014-09-11 2024-05-22 Immunis.AI, Inc. Methods of detecting prostate cancer
EP3789399A1 (en) 2014-11-21 2021-03-10 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
LT3221363T (lt) 2014-11-21 2020-08-10 Bristol-Myers Squibb Company Antikūnai prieš cd73 ir jų panaudojimas
GB201706747D0 (en) 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736343A (en) * 1995-08-18 1998-04-07 Landry; Donald Detection of organic compounds through regulation of antibody-catalyzed reactions
EP0862652A1 (en) * 1995-10-13 1998-09-09 IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) * 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
WO2002077174A2 (en) * 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
DE602004027797D1 (de) * 2003-03-28 2010-08-05 Faron Pharmaceuticals Oy Erhöhung des adenosin-spiegels durch cytokin-induzierte expression von cd73
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
WO2005000860A2 (en) * 2003-06-03 2005-01-06 The Regents Of The University Of California Compositions and methods for treatment of disease with acetylated disaccharides
EP1917528B1 (en) * 2005-08-24 2011-08-17 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
EP2021350B1 (en) * 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
AU2007273055B2 (en) * 2006-07-14 2014-05-01 The Regents Of The University Of California Cancer biomarkers and methods of use thereof

Also Published As

Publication number Publication date
DK2201376T3 (da) 2012-10-15
EP2201376B1 (en) 2012-08-08
PL2201376T3 (pl) 2013-01-31
EP2201376A4 (en) 2011-03-23
CY1113403T1 (el) 2016-06-22
FI20070795A0 (fi) 2007-10-24
KR20100059902A (ko) 2010-06-04
EP2503338B1 (en) 2014-12-24
PT2503338E (pt) 2015-03-05
DK2503338T3 (en) 2015-03-09
HRP20120743T1 (hr) 2012-10-31
PL2503338T3 (pl) 2015-06-30
ES2532361T3 (es) 2015-03-26
EP2201376A1 (en) 2010-06-30
CY1116089T1 (el) 2017-02-08
CA2702635A1 (en) 2009-04-30
KR20160029869A (ko) 2016-03-15
ES2389751T3 (es) 2012-10-31
EP2503338A2 (en) 2012-09-26
PT2201376E (pt) 2012-08-20
JP2012159514A (ja) 2012-08-23
EP2503338A3 (en) 2013-03-13
JP2011501176A (ja) 2011-01-06
SI2503338T1 (sl) 2015-06-30
JP5619810B2 (ja) 2014-11-05
JP4982610B2 (ja) 2012-07-25
US20100209942A1 (en) 2010-08-19
HRP20150181T1 (hr) 2015-06-19
WO2009053523A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
PL2201376T3 (pl) Nowy biomarker do monitorowania rozwoju chorób i do oceny skuteczności leczenia
GB0724735D0 (en) Methods and biomarkers for diagnosing and monitoring psychotic disorders
GB0701626D0 (en) Methods and biomarkers for diagnosing and monitoring psychotic disorders
IL219210A0 (en) Biomarkers and methods for measuring and monitoring inflammatory disease activity
ZA201108907B (en) New biomarkers for assessing kidney diseases
EP2043617A4 (en) SYSTEM FOR MANAGING THERAPY AND MONITORING SUBSTANCE TO BE ANALYZED AND METHODS THEREFOR
IL246042A0 (en) Methods and systems for evaluating clinical expenses
GB2446124B (en) Device for Monitoring Respiration
GB2450351B (en) Monitoring an Immunoassay
IL179930A0 (en) Tvms - a total view monitoring system
PL2185068T3 (pl) Monitorowanie płodu
IL195054A0 (en) Methods and apparatus for identifying disease status using biomarkers
GB0705126D0 (en) Monitoring physical activity
EP2486233A4 (en) Formation testing planning and monitoring
IL217725A0 (en) Means and methods for diagnosing thyroid disorders
GB2444848B (en) Battery life monitor
GB0724200D0 (en) Battery life monitor
GB0720433D0 (en) Usage monitoring
GB0521098D0 (en) Methods for diagnosing and monitoring psychotic disorders
BRPI0814074A2 (pt) Método para a fabricação de 4-isopropil-3-metilfenol e sua utilização
ZA200905528B (en) Monitoring of tickets
GB0622351D0 (en) Non-invasive monitoring
GB0822262D0 (en) Monitoring computer usage
GB0822087D0 (en) Monitoring computer usage
AU2009902698A0 (en) Agents and methods for diagnosing a condition